Previously, we designed a DNAzyme (b1DE) targeting the human b1 integrin subunit, which efficiently digested the mRNA of the b1 integrin subunit and downregulated b1 integrin expression in endothelial cells. This DNAzyme blocked the adhesion of endothelial cells and abolished their ability to form microcapillary tubes in Matrigel. In our present study, we demonstrate that b1DE effectively inhibited neovascularization in Matrigel plugs (BALB/c mice, n ¼ 20) and solid human carcinoma tumors developed in nude mice (BALB/cA nude (nu-/-)-B6.Cg-Foxn1 nu ) (n ¼ 30) using prostate carcinoma cells PC-3 (n ¼ 15) and colon adenocarcinoma cells CX1.1 (n ¼ 15). When injected intratumorally, it significantly reduced the tumor size and number of microvessels developed by both CX1.1 and PC-3 cells within the 3 weeks of experiment duration. Thus, DNAzymes targeting b1 integrin genes can inhibit multiple key tumorigenic processes in vitro and in vivo and may serve as useful anti-cancer agents.
Introduction
In the past decade, a number of RNA-cleaving deoxyribozymes (DNAzymes) have been developed using a combinatorial technique described as 'in vitro selection'. 1 The most typical DNAzyme, known as '10-23', has a catalytic central domain of 15 highly conserved deoxyribonucleotides, flanked by two substrate-recognition domains that can vary in length and sequence. 2 The 10-23 DNAzymes can be designed to cleave effectively between any unpaired purine and pyrimidine of mRNA transcripts. 2 As they show high substrate flexibility, DNAzymes are frequently developed specifically to recognize the AU nucleotides of the start codon, which are usually located within the region having little secondary structure. Thus, DNAzymes bind the RNA substrate through complementary base-pairing, cleave their target mRNA in a gene-specific manner, 3 and can be used to control even complex biological processes. As examples, DNAzymes that were designed to (a) cleave b1 and b3 integrin mRNA-reduced expression of the targeted integrin subunits in endothelial cells and blocked proliferation, migration and network formation in a fibrin and Matrigel matrix, 3 and (b) cleave 12-lipoxygenase mRNA specifically downregulated the expression of this protein and its metabolites, known to play a crucial role in tumor angiogenesis. 4 In addition, (c) DNAzyme made to cleave VEGFR2 mRNA degraded its substrate efficiently and inhibited the proliferation of endothelial cells with a concomitant reduction of vascular endothelial growth factor (VEGF)R2 mRNA, and blocked tumor growth in vivo, 5 and (d) a DNAzyme for cleaving survivin mRNA markedly increased apoptosis and inhibited the growth of human pancreatic carcinoma cells. 6 These agents have been used in a number of in vivo applications to inhibit the expression of their target gene 7 and their dependent genes. 8 The capacity of DNAzymes to block the development of a diverse range of pathologies in animal models 5, [7] [8] [9] [10] [11] suggests their potential use as therapeutic tools.
Integrin involvement in tumor cell migration and metastasis has been widely investigated and discussed. 12, 13 Integrins have direct effects in stimulating proliferation, preventing apoptosis in cancer cells and mediating proangiogenic interactions between endothelial cells and extracellular matrix. For these reasons, integrins have become attractive targets for drug development, and several effective integrin antagonists are now under clinical evaluation. The therapeutic potential of av integrin antagonists, both peptide antagonists and the anti avb3 monoclonal antibody LM609, has been evaluated in phase I and phase II clinical trials for patients with late stage cancer. [14] [15] [16] [17] Clinical trials in patients with solid tumors provided an early evidence indicating the clinical benefit in disease stabilization with their use in the settings of colorectal cancer, renal cell carcinoma and melanoma. Regulation of integrin expression at the level of protein synthesis, either by synthetic oligodeoxynucleotides 15, 16 or the viral-mediated infection of endothelial cells to express the antisense RNA endogenously, 18 has been suggested as an alternative method to inhibit angiogenesis in vivo. In addition to avb3, the collagen receptors a1b1 and a2b1 19 and other b1 integrin receptors 20 have been shown to play important roles in angiogenesis and tumor growth. 21 Integrin receptors play a primary role in the motility of cancer cells. They are involved not only in physically tethering cells to the matrix, but also in transmitting signals in both directions that regulate these processes. Changes in the expression of integrins induced by carcinogenesis are complex: (a) the expression levels of many different integrins can be upregulated during cancer progression. 22-25 (b) In some cells carcinogenesis is associated with a switch in integrin expression; for example, the major integrins a5b1 and a6b1 on normal hepatocytes are replaced by a1b1, a2b1 and a3b1, which are abundantly expressed in cancer cells. [26] [27] [28] This switch of integrin expression is associated with the acquisition of the migratory capacity, suggesting an important role for these integrins in cancer cell motility. Furthermore, several growth factors, which are abundantly expressed in the tumor microenvironment, are considered potent stimulators of the integrin expression. 29, 30 Recently, we have developed a DNAzyme that targeted and cleaved b1 integrin subunit mRNA in vitro and markedly reduced the adhesion and the migration of endothelial cells. It also abolished an endothelial cell capillary tube formation in fibrin and Matrigel. In this report we have evaluated its potential as a geneinactivating agent for inhibiting angiogenesis and tumor growth in vivo.
Materials and methods
Synthesis of DNAzyme to b1 mRNA DNAzyme to human b1 mRNA (hb1DE) was chemically synthesized on a solid support using an ABI-394 DNA Synthesizer as described before. 31 This particular DNA sequence (hb1DE, 5 0 CAAGGTGAGg 1 g 2 c 3 t 4 a 5 g 6 c 7 t 8 a 9-c 10 a 11 a 12 c 13 g 14 a 15 AATAGAAG 3 0 ) was previously analyzed for its enzymatic activity, specificity, exonuclease resistance and ability to inhibit an expression of human b1 integrins in endothelial cells. 3 It also inhibited adhesive properties of cells as evaluated by analysis of both adhesion and migration to fibronectin, laminin and collagen. To increase the stability of this DNAzyme, modified oligonucleotides with 2 0 -O-methyl-substituted residues were introduced at both the 5 0 and 3 0 sides. This analog of hb1DE was used throughout this work. In addition, the inactive human DNAzyme hb1DE 5C ), L-glutamine (2 mM). NIH 3T3 cells were cultured in DMEM medium with 10% fetal bovine serum, streptomycin (100 mg ml
À1
) and penicillin (100 U ml
). All cell cultures were maintained at 37 1C in the presence of 5% CO 2 . For experiments, cells were transferred to 6-well dishes and used at 70% confluency in the MEM-a or DMEM supplemented with the components mentioned above. DNAzymes were mixed with LipofectAMINE Reagent (5 mg ml À1 ) (GIBCO BRL, Invitrogen, Carlsbad, CA) and suspended in Opti-MEM-reduced medium containing 2 mM MgCl 2 to obtain a final concentration of 1 mM. Transfection was performed for 6 h according to the manufacturer's protocol. After incubation for 12 h in a corresponding medium supplemented with 10% FBS, cells were detached with trypsin/EDTA and used for experiments. Cell viability was determined microscopically by trypan blue exclusion and only cell cultures having less than 1% dead cells were included in the study.
Relative quantitative reverse transcription PCR assays of mRNA Total mRNA was purified from 1 Â 10 7 cells using a Total RNA Prep Plus Kit (A&A Biotechnology, Gdynia, Poland). The first strand cDNA was synthesized according to the manufacturer's instruction using (dT) 20 primer. Then, b1 mRNA was determined by relative quantitative RT-PCR using glyceraldehyde-3-phosphate dehydrogenase mRNA (GAPDH mRNA) as an internal standard. The human b1 mRNA assay employed the following oligodeoxyribonucleotide primers: 5 0 GTAACCAACCG TAGCAAAGG 3 0 and 5 0 ATGTCTGTGGCTCCCCT GATC 3 0 . To amplify mouse b1 mRNA, the following primers were used: 5 0 TCT CACTAGATTGAATGA CAC 3 0 and 5 0 ACATACATCACTGGGAATTC 3 0 . Usually, samples were denatured at 95 1C for 5 min then cooled down on ice. After that enzyme was added, then 35 primer extension cycles consisting of a 30 s denaturation step at 94 1C, a 30 s annealing step at 60 1C (48 1C for mouse b1 mRNA) and a 30 s polymerase extension step at 72 1C were performed. Finally, each reaction was terminated with a 15 min elongation step at 72 1C. To detect glyceraldehyde-3-phosphate dehydrogenase (GADPH), the same protocol was used with oligodeoxyribonucleotide primers 5 0 GAGAGATGATGACCCTTTTGGC 3 0 and 5 0 CATCACCATCTTCCAGGAGCG 3 0 . The final products, human b1 (109 bp), mouse b1 (210 bp) and GAPDH (154 bp) mRNAs, were separated by electrophoresis in 7% polyacrylamide gels in TAE buffer using the genetic size marker BenchTop 100 bp DNA Ladder (Promega, Madison, WI). Bands were visualized by UV light, the results were recorded photographically and analyzed densitometrically using an LKB Ultrascan XL Enhanced Laser Densitometer. Concentrations of mRNA for human and mouse b1 were normalized in each sample in relation to GAPDH mRNA.
Detection of b1 integrin subunit by western immunoblotting Subconfluent PC-3 and CX1.1 cells were grown for 6 h in the presence or absence of human b1DE or b1DE SC . After incubation for 12 h in a medium supplemented with 5% FBS cells, were washed with PBS and lysed in M-PER Mammalian Protein Extraction Reagent (PIERCE, Rockford, IL) supplemented with protein inhibitor cocktail (Roˆche, Basel). In all, 30 mg samples of total protein from cells mock-transfected or transfected with b1DE or b1DE SC were boiled with 5 Â concentrated sample buffer containing 2-mercaptoethanol then separated by SDS-PAGE 3 and electroblotted onto nitrocellulose membranes (BIO-RAD, Hercules, CA). The membranes were airdried and blocked in PBS containing 5% skim milk and 0.05% Tween 20. The membrane was incubated with rabbit polyclonal anti-human b1 integrin peptide antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) and then the level of b-actin was detected with rabbit polyclonal antibody (Abcam, Cambridge, MA). Immunodetection was accomplished using the enhanced chemiluminescence kit (ECL Kit, PIERCE), then films were scanned and protein bands quantitated using the GelImage system (Pharmacia LKB, Midland, Canada). To quantify the densitometric scans, the background was subtracted and the area for each protein peak was determined.
Animals Six-to 8-week-old female BALB/c and BALB/cA nude (nu-/-)-B6.Cg-Foxn1 nu mice were purchased from Animal Quarters of Medical University, Lodz, Poland and Taconic Europe, Ejby, Denmark respectively. Mice were housed under pathogen-free conditions in microisolator cages with laboratory chow and water available ad libitum. For experiments animals were divided into three groups (n ¼ 5), anesthetized before all invasive procedures and observed until fully recovered. All experiments and procedures were reviewed by the Local Ethical Committee and performed in accordance with the EU polices regarding the human care and use of laboratory animals.
Matrigel plug assay
Matrigel plug assays were performed as described previously with modifications. 32 BALB/c mice (n ¼ 15) were anesthetized and injected at the abdominal midline with 0. , mice were divided into three groups, two of which received an injection of 1.25 mg mb1DE or mb1DE SC per tumor and the third received the vehicle buffer (control). Tumors were measured three times a week with a slide caliper, and their volumes were calculated by the formula [p/6 (w1 Â w2 Â w3)], where w1 represents the largest tumor diameter, w2 represents the smallest tumor diameter and w3 tumor height. Tumor tissue was homogenized (mechanical whipper, Janke & Kunkel IKA, ULTRA-TURRAX T25) with PBS, centrifuged (13 000 r.p.m., 5 min) then supernatant with hemoglobin was taken for analysis with Drabkin's reagent (Sigma). The level of hemoglobin derivative cyanmethemoglobin was measured by a spectrophotometer (wavelength 540 nm, CECIL CE 2011, 2000 SERIES), and the amounts of hemoglobin were calculated per 1 g of tumor.
Immunohistochemistry, quantification of angiogenesis Paraffin sections were mounted on SuperFrost slides, deparaffinized, then treated in a microwave oven in a solution of citrate buffer, pH 6.0 for 20 min (2 Â 360 W-5 min, 2 Â 180 W-5 min) and transferred to distilled water. Endogenous peroxidase activity was blocked by 0.3% hydrogen peroxide in distilled water for 30 min, then sections were rinsed with Tris-buffered saline (TBS, DakoCytomation, Glostrup, Denmark) and incubated overnight at 4 1C with rat monoclonal anti CD34 (MEC 14.7; Abcam) at a dilution of 1:100. Afterwards polyclonal rabbit anti-rat immunoglobulins/HRP (P0450; DakoCytomation, Denmark) prepared according to the instructions of the manufacturer was used. Visualization was performed by incubating the sections in a solution of 3,3 0 -diaminobenzidine (DakoCytomation, Denmark). After washing, the sections were counter-stained with hematoxylin and coverslipped. For each sample a negative control was processed. Negative controls were carried out by incubation in the absence of the primary antibody and always yielded negative results.
Histological morphometry was performed by means of an image analysis system consisting of an IBM-compatible computer equipped with an optical mouse, Indeo Fast card (frame grabber, true-color, real-time), produced by Indeo Taiwan (San Francisco, CA) and color TV camera (Panasonic, Osaca, Japan) linked to a Carl Zeiss Jenaval microscope (Jena, Germany). This system was programmed (MultiScan 8.08 software, produced by Computer Scanning Systems, Warsaw, Poland) to calculate the number of objects (semiautomatic function). The microvessels were determined by counting all CD34-positive structures in a sequence of 10-15 consecutive computer images of 250 Â high power fields of 0.047914 mm 2 each. Any immunoreactive endothelial cell or endothelial cell cluster which was separated from microvessels was considered to be a single countable microvessel. Vessel lumens were not necessary for a structure to be defined as a microvessel. The mean values of microvessels with or without lumen were calculated per mm 2 .
For pathomorphological examination the tumor specimens were fixed in 4% buffered formaldehyde and were routinely processed for paraffin embedding. Sections were cut at 4 mm, dewaxed and stained with hematoxylin and eosin (H&E). Figure 1 Human b1DE (hb1DE) blocks expression of b1 integrin subunit in PC-3 and CX 1.1 cells as does mouse b1DE (mb1DE) in NIH 3T3 cells. PC-3 and NIH 3T3 cells were incubated for 6 h with human and mouse b1DE or b1DE SC (1 mM), then washed with PBS and used to measure b1 mRNA by relative quantitative RT-PCR (a). b1 integrin subunit from PC-3 and CX 1.1 cells was also separated by SDS-PAGE after extraction with SDS sample buffer, followed by western immunoblotting (b). Immunodetection of b1 was accomplished using an enhanced chemiluminescence kit. Anticancer activity of DNAzymes to b1 integrin mRNA J Niewiarowska et al software statistical program (Jandel Scientific, San Rafael, CA).
Statistical analysis

Results
Blockade of b1 integrin expression in carcinoma cells
We previously designed a 10-23 DNAzyme targeting the 1053-1070 (5 0 cttctattgctcaccttg 3 0 ) region of human b1 integrin mRNA. In mouse mRNA this sequence can be found in the 1129-1147 region and differs by only a single substitution of thymidine by adenine in the position 1133. Therefore, two types of DNAzymes, human and mouse b1DE, were generated. To protect the molecule from exonucleases, modified oligonucleotides with 2 0 -Omethyl-substituted residues were introduced at both the 5 0 and 3 0 ends. DNAzyme to human b1 integrin (hb1DE) specifically inhibited expression of this integrin subunit, measured at both mRNA and protein synthesis levels (Figure 1a and b) . Relatively short (6 h) incubation of PC-3 cells with hb1DE also resulted in significant reduction of b1 integrin subunit expression on their surface when compared with control (Po0.05), as detected by flow cytometry (Figure 1c) . Interestingly, the murine b1DE (mb1DE) had no effect on human b1 integrin synthesis in human cells but inhibited an expression of murine b1 integrin subunit in mouse NIH 3T3 cells (Figure 1a) .
b1DE inhibits vascularization of Matrigel plugs
To demonstrate that mb1DE can directly inhibit angiogenesis in vivo, in preliminary experiments Matrigel supplemented with bFGF was injected into BALB/c mice, forming semi-solid plugs. Twenty-four hours later, mice were treated with mb1DE or mb1DE SC every 2 days for a total of 7 days. Plugs without a growth factor had virtually no vascularization after 6 days (Figure 2 ). In contrast, plugs supplemented with bFGF and not-treated with mb1DE had extensive vascularization and vessels throughout the plug. Plugs taken from mice treated with 
]
Injection Control mβ1DE SC mβ1DE Figure 3 Mouse b1DE (mb1DE) reduces tumor growth of human prostate carcinoma xenografts. PC-3 cells were injected into male BALB/cA nude (nu-/-)-B6.Cg-Foxn1 nu mice (n ¼ 15) to develop solid tumors. Then, mice were divided into three groups (n ¼ 5), the first one being treated with mb1DE (1.25 mg per injection) administrated intratumorally every 2 days after tumor volume was assessed to be 150 mm 3 . The second group received control mb1DE SC under the same conditions, and the third one consisted of vehicle buffer-treated control mice. (A) mb1DE significantly reduces the volume of the carcinoma tumor. In (B), tumors before (a, b and c) and after administering the vehicle buffer, mb1DE SC or mb1DE (d, e and f) are shown. (g, h and i) ( Â 150) Representative cross sections of control, mb1DE SC and mb1DE-treated tumors, respectively, stained with H&E to demonstrate necrosis caused by mb1DE. Vasculogenesis was photographed (inserted panel) and evaluated in tumors based on hemoglobin content determined by using Drabkin's reagent (C). **po0.01.
1.25 mg mb1DE/injection had markedly reduced the vascularization of plugs. Furthermore, Matrigel plug angiogenesis was quantitated by measuring the content of hemoglobin with Drabkin's reagent. Treatment with mb1DE significantly (Po0.05) reduced the amount of hemoglobin in Matrigel plugs compared with control ones (Figure 2 ).
mb1DE inhibits growth of carcinoma solid tumors
To further analyze the antiangiogenic activity of mb1DE in vivo we established human PC-3 cell xenografts in male BALB/cA nude (nu-/-)-B6.Cg-Foxn1 nu mice. Figure 3 shows that solid prostate carcinoma growth in athymic nude mice is significantly inhibited by mb1DE when compared with control mb1DE SC . In this experiment, DNAzymes at 1.25 mg per injection, either active or inactive, were administered into solid PC-3 tumors every second day after the tumor volume was assessed to be 150 mm 3 . Mouse body weight was assessed at the beginning and at the end of the experiment. The active mb1DE caused profound sequence-specific inhibition of solid tumor growth and such inhibition was apparent even after the second administrations of DNAzyme ( Figure 3A ). Body weights of the mice were not adversely affected by active DNAzyme and animals gained weight (data not shown). Surprisingly, control mb1DE SC significantly inhibited the growth of solid prostate carcinoma tumors in athymic nude mice as well. Treatment of solid tumors with b1DE caused significant necrosis (Figure 3Bf ) confirmed by histological analysis (Figure  3Bi ). Histological examination revealed solid masses of tumor cells with only occasional glands. Both the cancer cells and nuclei displayed variation in size and shape. The nuclei were large and hyperchromatic, with large nucleoli. In addition to the cytological abnormalities the orientation of anaplastic cells was markedly disturbed. Control tumors contained several blood vessels directly on the tumor surface as well as blood vessels feeding into the tumor, visible on the underside of the skin ( Figure 3C ). By contrast, mb1DE-treated tumors had few or no blood vessels directly on the tumor surface, and visible blood vessels on the skin ran adjacent to the tumor rather than directly into the tumor. Such antiangiogenic activity of mb1DE was fully confirmed by an evaluation of hemoglobin content in control and active DNAzymetreated tumors (Po0.01) ( Figure 3C ).
To quantify blood vessels in PC-3 tumors from control and mb1DE-treated animals, tissue sections were stained immunochemically with monoclonal antibody to CD34 (Figure 4a ). An immunohistochemical study showed a positive staining on vascular endothelial cells. Microvessels without lumen were CD34-positive as well. Immunostaining demonstrated both blood vessels with wide lumen and with markedly narrowed lumen located within tumor stroma. In areas of extensive necrosis the number of blood vessels was scant. Treatment with mb1DE did not influence the number of CD34-positive microvessels without lumen but caused a statistically significant decrease (Po0.01) in the number of tumor blood vessels containing lumen when compared with control ( Figure 4b ). Microscopic evaluation revealed that in mb1DE-treated tumors, vascular stroma was scant and large areas of tumor cells underwent ischemic necrosis. Figure 5 shows that mb1DE also efficiently blocked tumor growth of human colon adenocarcinoma. In these experiments PC-3 cells were substituted by CX1.1 cells to develop solid tumors in female BALB/cA nude (nu-/-)-B6.Cg-Foxn1 nu mice. All experiments were performed exactly as described for human solid PC-3 tumors. When administered intratumorally at 1.25 mg per injection, mb1DE showed direct, sequence-specific inhibition of colon solid tumor growth by targeting mouse b1 integrins, causing necrosis after the second dose (data not shown). Necrosis of tumor cells was wide-spread and extensive in comparison with controls and mb1DE SC -treated tumors (Figure 5Bf ). Also in this system, control mb1DE SC caused profound inhibition of CX1.1 tumor growth when compared with mice given only the vehicle buffer. Histological examination revealed well-differentiated carcinoma with obvious glandular or trabecular elements. As in the case of PC-3 tumors, the nuclei and nucleoli of the CX1.1 tumors were large. Chromatin was often coarsely clumped and distributed along the nuclear membrane. Mitotic figures were less abundant than in solid PC-3 cancer sheets. Cancer cells had focally lowered cohesiveness and sheets of large masses of tumor cells grew in an anarchic, disorganized fashion (Figure 5Bg-i) . There was a significant reduction in tumor hemoglobin content (Po0.01) ( Figure 5C ) and in the number and size of the blood vessels in the CX1.1 tumors of mice treated with DNAzyme (Po0.05) (Figure 6b ) comparing with those of control tumors. The above results suggest that b1DE could affect tumor growth through its effects on tumor endothelial cells.
Unexpectedly, prolonged exposure of mice to mb1DE SC markedly inhibited tumor growth in both in vivo systems. In in vitro experiments, the control DNAzyme containing binding arms with a scrambled sequence did not show any activity after treating NIH3T3 cells (Figure 1a this discrepancy, its sequence was subjected to BLAST analysis and showed the presence of a 15-residue stretch of nucleotides that was complementary to myomesin 1 (skelemin) mRNA. There is strong evidence that skelemin by interacting with cytoplasmic tail of integrin b subunits influences conversion of integrins into the activating state 33 . Therefore, we have analyzed the effect of mb1DE SC on skelemin expression in cancer cell lines (PC3, CX1.1) measured at mRNA and protein levels (data not shown). Our studies showed that mb1DE SC due to the antisense activity reduced the expression of skelemin in cancer cell lines, indicating that its inhibitory effect observed in vivo may result from downregulation of skelemin-dependent activation of b1 integrins in tested mice.
Discussion
The strategy of targeting angiogenesis to inhibit cancer progression has received increasing attention in recent years. Among a number of proteins that are involved in this process are integrins, cell surface receptors interacting with extracellular ligands, which were found to be ideal pharmacological targets. Three different types of function-blocking compounds have been reported to date, that is, antibodies, peptides (mostly RGD based), and nonpeptidic molecules. b1-integrins are particularly crucial in angiogenesis, and in fact, b1-integrin null embryos die early in gestation and do not develop far enough to begin to produce vasculature. 32, 34 Moreover, b1-null embryoid bodies are resistant to VEGF-induced proliferation and branching. 35 Although integrins are present in all cells, their expression changes significantly when cells are activated and show increased mobility. For example, a1b1, a3b1 and a5b1 are expressed at low levels in quiescent vessels but at minimum, a5b1 is upregulated during angiogenesis. 36 VEGF stimulation of endothelial cells induced an increased regulation of expression in the collagen receptors a1b1 and a2b1. Moreover, collagen I ligation of a1b1 and a2b1 is a decisive step in initiating cord formation of endothelial cells. 37 Similarly, avb3, avb5 and a2b1 are scarcely present in quiescent vessels but are common in sprouts 38 and only avb3 expression is enhanced upon bFGF treatment. 39 Integrins also play a dominant role in metastasis, a process characterized by altered cancer cell motility and adhesion to surrounding cells and tissues. 40, 41 The roles for specific integrins have been described in a number of tumor types, and often multiple integrins are involved within a single tumor type. For example, during attachment to lymph nodes, melanoma cells utilize aVb3-vitronectin binding interactions, whereas breast cancer cells utilize a3b1-fibronectin binding. 42 Signaling through the a2b1 and a3b1 pathways, converging on integrin-linked kinase, stimulates motility and invasiveness of ovarian cancer cells in vitro. The results of our study demonstrate that blockade of b1 integrin expression by intratumoral administration of DNAzyme targeted at b1 integrin subunit mRNA inhibits angiogenesis in the growth of human solid tumors and in two in vivo models. b1DE effectively inhibited neovascularization stimulated by bFGF added to Matrigel plugs and neovascularization stimulated by tumor cells present in human carcinoma PC-3 and CX1.1 xenografts. Consistently, there was marked cell death in the peripheral regions of the tumor accompanied by a reduction in blood vessel density, further supporting the antiangiogenic mechanism of the DNAzyme. These data, together with recently published studies in which murine animal models of cancer were used, have proven the applicability and high efficiency of DNAzymes to control solid tumor growth. Up to now several proteins were targeted with DNAzymes in in vivo studies. Cleavage of vascular endothelial growth factor receptor 2 (VEGFR2) mRNA by specific DNAzyme was found to cause an approximately 75% reduction of tumor size compared with the saline-injected control group. 5 Similarly, DNAzymes specific to c-Jun mRNA suppressed solid SCC tumor growth and tumor angiogenesis in severe combined immunodeficient mice. These findings indicate that DNAzymes to this transcription factor may potentially be useful as inhibitors of cutaneous carcinoma. 44 This DNAzyme also inhibited VEGF-induced neovascularization in the rat cornea and solid melanoma growth in mice. 5 DNAzyme targeting a specific motif in the 5 0 untranslated region of Egr-1 mRNA blocked angiogenesis in subcutaneous Matrigel plugs in mice and inhibited xenografted MCF-7 human breast carcinoma growth in nude mice. Several earlier studies have shown the applicability of DNAzymes against Egr-1 in non-cancer models, mainly cardiovascular disease models. 7 Altogether, these results indicate that DNAzymes, smallmolecule gene-targeting agents, may be useful as both direct and indirect anti-cancer agents.
To sum up, intratumoral delivery of DNAzymes targeting b1 integrins specifically inhibits tumor xenograft growth and indicates that these compounds affect tumor growth by directly blocking angiogenesis.
